Ns

29%

39%

39%

High nonrelapse mortality and relapse

PFS, progression-free survival; OS, overall survival; Flud, fludrabine; BEAM, BCNU/etoposide/cytarabine/melphalan; a Personal communication MB Maris, Fred Hutchinson Cancer Research Center.

PFS, progression-free survival; OS, overall survival; Flud, fludrabine; BEAM, BCNU/etoposide/cytarabine/melphalan; a Personal communication MB Maris, Fred Hutchinson Cancer Research Center.

newer anti-B-cell monoclonal antibodies such as ritux-imab have no effect. Corradini et al.56 recently reported a phase II reduced-conditioning trial in 15 relapsed and 2 primary refractory peripheral T-cell NHL patients. Patients received thiotepa, fludarabine, and cyclophosphamide followed by blood stem cells obtained from sibling-matched (N = 14), sibling one-antigen mismatched (N = 2), and matched-unrelated donors (N = 1). Two-year nonrelapse mortality was 6% and 12 patients attained complete remission. Three-year progression-free and overall survivals were 64 and 81%, respectively.

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook


Post a comment